Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer.
نویسندگان
چکیده
Ovarian cancer is typically a disease of elderly women, usually occurring after menopause with a peak incidence in the eighth decade of life. Elderly patients are more likely to suffer the adverse effects of chemotherapy, which may influence successive lines of treatment. We describe the case of an elderly woman with platinum-sensitive ovarian cancer treated with several lines of chemotherapy who developed acute cardiogenic pulmonary edema with her first line of therapy, which included paclitaxel, and her fourth line containing gemcitabine. However, a complete regimen of pegylated liposomal doxorubicin in association with oxaliplatin was well tolerated. Other authors have reported absence of cardiotoxicity with liposomal doxorubicin in their study populations, but no mention was made of patients with a known prior susceptibility to transient heart failure when treated with other chemotherapeutic agents. Our case provides evidence that even in these more difficult-to-treat cases, where cumulative cardiotoxicity may be relatively unpredictable, liposomal doxorubicin does not affect cardiac function.
منابع مشابه
Pegylated liposomal doxorubicin in ovarian cancer
The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enha...
متن کاملA journey in anthracycline-induced cardiotoxicity with emphasizing on doxorubicin: a review article
Cancer is the second leading cause of death in the United States and has become a health problem worldwide. The reported incidence of new cancer cases is estimated at 19.3 million, with a mortality rate of 10 million in the world in 2020. There are several therapeutic approaches for cancer, including chemotherapy. Chemotherapy is consuming anti-neoplastic drugs, alone or in combination. However...
متن کاملPrevention from Doxorubicin Cardiotoxicity by Available Protective Agents in Iran
Doxorubicin, used in pediatric chemotherapy regimens, has cardiotoxic effects. Dexrazoxane is co-administrated with doxorubicin to prevent its cardiotoxicity. Here we have explored some alternative food or drugs to be used in absence of dexrazoxane since it’s not readily available in Iran at this time. Keywords: Pediatric, chemotherapy, doxorubicin, cardiotoxicity, dexrazoxane, Iran.
متن کاملSkin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature.
Pegylated liposomal doxorubicin (PLD) is a form of doxorubicin enclosed in pegylated liposomes. In contrast to conventional doxorubicin, PLD is characterized by a lower incidence of cardiotoxicity and myelosuppression. However, it induces specific mucocutaneous side effects, particularly palmar-plantar erythrodysesthesia (PPE). Other dermal manifestations, such as intertrigo-like dermatitis, di...
متن کاملSkin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
Liposomal pegylated doxorubicin is an encapsulation form of doxorubicin, with an improved pharmacokinetic profile and the ability to selectively accumulate into tumor tissue. As a result, the tolerated dose of the drug can be increased, followed by a reduced incidence of neutropenia and cardiotoxicity in comparison to doxorubucin treatment. However, a common adverse dose-schedule limiting effec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Tumori
دوره 93 2 شماره
صفحات -
تاریخ انتشار 2007